What type of study is this?

September 10, 2025

Data from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma

View Full Paper

Ask AI

Bookmark

Authors

MUMireia Uribe‐HerranzHospital Clínic de Barcelona AOAina Oliver‐CaldésAmyloidosis Foundation NMNeus Martínez-MicaeloInstitut d'Investigació Sanitària Pere Virgili

Discussion

Member takes

Implication

Observational analysis identifies metabolites and microbiota linked to CAR-T therapy outcomes in myeloma, indicating potential for personalized treatment.

Key Points

Succinate was associated with CAR T-cell persistence and phenotypes, and metabolic profiles significantly correlated with treatment efficacy.
Specific gut microbiota like Acidaminococcaceae showed associations with clinical outcomes in CAR-T therapy for myeloma patients.
This analysis utilized murine myeloma models to demonstrate the impacts of diet on CAR T-cell functionality and tumor control.
Integrated models indicate microbial and metabolic factors could enhance risk assessment for myeloma patients undergoing CAR-T therapy.

Cite This Study

Uribe‐Herranz et al. (2025) studied this question.

synapsesocial.com/papers/68c189ca9b7b07f3a0612e56 https://doi.org/10.1158/2643-3230.c.8014450

View Full Paper

Ask AI

Bookmark

Implication

Observational analysis identifies metabolites and microbiota linked to CAR-T therapy outcomes in myeloma, indicating potential for personalized treatment.

Data from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma

Discussion

Member takes

Implication

Key Points

Cite This Study

Data from Microbiota Shape Metabolic and Immune Determinants of CAR-T Therapy and Correlate with Outcomes in Myeloma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider